Sign in

CIK 0000875045

  • Large accelerated filer

BIOGEN INC.

Sign in to watch
Ticker
BIIB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
330112644
Phone
+1 617-679-2000
Business address
225 BINNEY STREET, CAMBRIDGE, MA, 02142
Former names
BIOGEN IDEC INC., BIOGEN IDEC INC, IDEC PHARMACEUTICALS CORP / DE, IDEC PHARMACEUTICALS CORP / CA
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2016-06-01 Ehlers Michael D EVP, Research and Development Grant or award · Restricted Stock Unit +7,320 7,320
2016-06-01 SCANGOS GEORGE A Chief Executive Officer Sale −487 $287.97 $140K 55,778
2016-05-31 SCANGOS GEORGE A Chief Executive Officer Sale −3,368 $290.00 $977K 56,265
2016-05-25 SCANGOS GEORGE A Chief Executive Officer Sale −157 $280.00 $44K 59,633
2016-05-02 Vounatsos Michel EVP & Chief Commercial Officer Grant or award · Restricted Stock Unit +9,520 9,520
2016-05-02 SCANGOS GEORGE A Chief Executive Officer Sale −487 $274.74 $134K 59,790
2016-05-01 COVINO GREGORY F VP, Chief Accounting Officer Exercise or conversion +348 3,119.82
2016-05-01 COVINO GREGORY F VP, Chief Accounting Officer Shares withheld for taxes −113 $274.99 $31K 3,006.82
2016-05-01 COVINO GREGORY F VP, Chief Accounting Officer Exercise or conversion · Restricted Stock Unit −348 0
2016-04-06 Koppel Adam EVP, Strategy and Bus. Dev. Sale −102 $275.00 $28K 1,848.11
2016-04-06 SCANGOS GEORGE A Chief Executive Officer Sale −157 $280.00 $44K 60,277
2016-04-02 Artavanis-Tsakonas Spyridon EVP, Chief Scientific Officer Exercise or conversion +975 3,608.97
2016-04-02 Artavanis-Tsakonas Spyridon EVP, Chief Scientific Officer Shares withheld for taxes −459 $260.54 $120K 3,149.97
2016-04-02 Artavanis-Tsakonas Spyridon EVP, Chief Scientific Officer Exercise or conversion · Restricted Stock Unit −975 0
2016-04-01 Cox John EVP Pharmaceutical Oper & Tech Grant or award +8,444 39,045.24
2016-04-01 SCANGOS GEORGE A Chief Executive Officer Sale −487 $258.83 $126K 60,434
2016-03-01 SCANGOS GEORGE A Chief Executive Officer Sale −487 $261.37 $127K 60,921
2016-02-25 Sandrock Alfred EVP CMO Neuro & Neurodegenerat Sale −183 $261.90 $48K 7,990
2016-02-25 Karaboutis Adriana EVP, Tech, Bus. Sol & Corp Aff Sale −84 $261.90 $22K 8,127
2016-02-23 Clancy Paul J Executive VP and CFO Exercise or conversion +579 27,143

Page 70 of 73 · 1,456 trades